n2779_x119-img003.jpg
With new CEO, Veracyte outlines €260M deal for French test maker HalioDx and global cancer testing expansion | Fierce Biotech
StockWatch: Investors, Analysts Debate Background of New Illumina CEO
How could the STAMPEDE trial shape prostate cancer care? - Oncology Central
Helix Expands Focus to Population Health Solutions and Appoints Illumina Veteran Marc Stapley as CEO
Illumina Inc. Posts Q3 Revenue of $607 Million
Veracyte, Inc. | LinkedIn
Marc Stapley - CEO at Veracyte | The Org
Marc Stapley - CEO at Veracyte | The Org
Illumina Appoints Marc Stapley as Senior Vice President and Chief Financial Officer
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Test Availability | Clinical Lab Products
Marc Stapley Net Worth (2023) - GuruFocus.com
Veracyte, Illumina partner to provide IVD tests on NextSeq 550Dx device
Marc Stapley - Veracyte
Illumina Appoints Marc Stapley as Senior Vice President and Chief Financial Officer
Marc Stapley Net Worth (2023) | wallmine
Illumina CFO Marc Stapley: Learn the Business Inside and Out - WSJ
1 Huge Reason to Buy Illumina, Inc. Stock Now | The Motley Fool
Illumina Moving Forward With San Diego Expansion, 300 New Jobs | BioSpace
Pharma startup names veteran exec to board – TechCentury
StockWatch: Investors, Analysts Debate Background of New Illumina CEO
Illumina: Unidentified Financing Operation? - by Mike
Glaukos - Investors - Governance & Sustainability - Board of Directors - Person Details
Illumina Executive Team | Comparably
n2779_x119-img002.jpg
